Drug updated on 11/9/2023
|Injection (intravenous; 1700 mg/34 mL (50 mg/mL)
| Ongoing and
- For the treatment of adult and pediatric patients with inhalational anthrax due to bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
Product Monograph / Prescribing Information
|Raxibacumab Prescribing Information.
|Emergent BioSolutions Inc., Gaithersburg, MD
Systematic Reviews / Meta-Analyses
|Antitoxin Use in the Prevention and Treatment of Anthrax Disease: A Systematic Review.
|Clinical Infectious diseases
Clinical Practice Guidelines
|Virginia Department of Health Anthrax: Guidance for Healthcare Providers Key Medical and Public Health Interventions after Identification of a Suspected Case.
|Virginia Department of Health
|Extrapolation and dosing recommendations for raxibacumab in children from birth to age < 18 years.
|British Journal of Clinical Pharmacology